ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer
A novel nomogram to identify candidates for active surveillance among patients with ISUP Grade Group 1 or ISUP Grade Group 2 prostate cancer, according to multiparametric magnetic resonance imaging findings
Indirect comparisons of efficacy between combination approaches in metastatic hormone-sensitive prostate cancer: a systematic review and network meta-analysis
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study
Lancet oncology, Volume 20, Issue 11, November 2020, Pages 1518-1530
Detection of recurrent prostate cancer using prostate-specific membrane antigen positron emission tomography in patients not meeting the phoenix criteria for biochemical recurrence after curative radiotherapy
Analysis of AR-FL and AR-V1 in whole blood of patients with castration resistant prostate cancer as a tool for predicting response to abiraterone acetate
Veterans affairs cooperative studies program study #553: chemotherapy after prostatectomy for high-risk prostate carcinoma: a phase III randomized study